| Literature DB >> 29017053 |
Palaniraja Thandapani1, Iannis Aifantis2.
Abstract
The clinical success of the BH3-mimetic venetoclax has generated increasing interest to target BCL2 family proteins in oncology. In this issue of Cancer Cell, Reyna and colleagues demonstrate the potential of a pharmacological activator of the pro-apoptotic protein BAX to suppress acute myeloid leukemia both alone and together with venetoclax.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29017053 DOI: 10.1016/j.ccell.2017.09.009
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743